Silo Pharma, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated results. Silo is a development-stage biopharmaceutical company; reported revenue is primarily license-fee amortization, not product sales.
Business context
The company is developing four principal programs: SPC-15 (stress-induced disorders, including PTSD), SP-26 (chronic pain and fibromyalgia), SPC-14 (Alzheimer’s disease) and SPU-16 (CNS-targeted peptide research, initially for multiple sclerosis). Its programs remain research and development-stage.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $18,026 | $18,026 |
| Gross profit / margin | $16,566 / approximately 91.9% | $16,566 / approximately 91.9% |
| Operating expenses | $896,079 | $820,051 |
| Operating loss | $879,513 | $803,485 |
| Net loss | $801,667 | $906,396 |
| Basic and diluted loss per share | $0.28 | $0.29 |
| Cash used in operations | $838,179 | $692,688 |
Revenue was entirely from one licensee, Aikido Pharma, and was unchanged year over year. R&D expense increased 56.8% to $318,240; professional fees fell 12.8% to $318,427. Net loss improved 11.6%, mainly because Q1 2023 included a $166,034 penalty for early termination of a certificate of deposit; Q1 2024 also benefited from higher interest income.
At March 31, 2024, cash and cash equivalents were $2.67 million and short-term investments were $4.08 million, totaling approximately $6.74 million. Working capital was $6.00 million, down $901,354 from year-end 2023. Total assets were $6.94 million and total liabilities were $1.65 million. No conventional borrowing or debt balance is reported; liabilities consist mainly of accounts payable/accruals and deferred revenue. Treasury-stock purchases used $115,452 in the quarter. Management says available cash and liquid investments should fund obligations for at least 12 months from the filing date.
Accumulated deficit was $11.67 million. Operating cash use exceeded the prior-year quarter by $145,491. The company reported no income-tax provision.
Changes, outlook and risks
- Operating expenses rose 9.3%, led by higher R&D, while operating loss widened 9.5%. Net loss nevertheless narrowed because other income/expense improved materially from the prior-year CD penalty.
- Management expected to complete the SPC-15 Columbia license agreement in the first half of 2024, seek an FDA pre-IND meeting in the first half of 2024, and obtain further SPC-14 preclinical results during 2024. These are forward-looking expectations, not reported outcomes.
- Research and development agreements had $827,125 of future amounts due for the year ending March 31, 2025. The Columbia research project was estimated to be 90% complete; $330,825 remained unpaid on a scheduled payment and a further $143,607 was due upon completion.
- The proposed ketamine joint venture with Zylö Therapeutics had not been formed as of the filing date. The company stated it did not intend to continue with Zylö and had entered into an agreement to develop a ketamine polymer implant.
- Key risks include needing additional funding, clinical research timing and cost, regulatory approval, intellectual-property protection, commercialization and market acceptance. Revenue concentration in one licensee and reliance on research/licensing partners add risk. The company reported no material legal proceedings and no material change to its previously disclosed risk factors.
- Management concluded disclosure controls were ineffective at March 31, 2024, citing limited staffing, lack of segregation of accounting duties, and inadequate system and manual controls. It expected material weaknesses could continue until staffing expands.
- The board extended the $1 million share-repurchase program through April 30, 2024. The company repurchased 72,790 shares for $115,452 during Q1 and a further 30,065 shares for $57,661 from April 1 through April 30.
Most important facts for investors to verify
- Whether the stated 12-month liquidity runway remains adequate as operating cash burn and contracted research spending continue.
- Progress and costs for SPC-15, SPC-14, SP-26 and SPU-16, including the expected Columbia license and FDA engagement; confirm whether stated milestones were achieved after the filing.
- Collection and timing of any Aikido-related milestone or royalty income; current revenue is minimal and entirely concentrated in one licensee.
- Research commitments and payables, particularly the $827,125 scheduled for the year ending March 31, 2025 and Columbia-related amounts.
- Remediation of the disclosed material weaknesses and the reliability of future financial reporting.
- Share-count reconciliation: the filing reports 2,833,451 shares outstanding at March 31, while its cover reports 2,803,386 at May 13 and separately notes treasury shares; verify the effect of subsequent repurchases and the reported share figures.